Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary

Intra-Cellular Therapies

01/03/2022 18:05

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of $1.05​​ per share for the quarter ended in
December. The mean expectation of ten analysts for the quarter
was for a loss of 99 cents per share.
    * Revenue rose 106.1% to $25.67 million from a year ago; 
analysts
expected $24.96 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of $1.05​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Intra-Cellular Therapies Inc shares had risen by 6.0% this
quarter.
    * The company reported a quarterly loss of $85.73 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $64.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 1 at 06:05 p.m.  ​All
figures in US dollars unless otherwise stated